title: Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
abstract: By retrospectively analyzing 288 patients with de novo myelodysplastic syndrome (MDS), we sought to determine the prevalence and clinical characteristics of bone marrow eosinophilia and basophilia that were detected at presentation. Bone marrow eosinophilia and basophilia were defined as a differential count of each cell type exceeding 5.0% and 1.0%, respectively. Of 288 patients with MDS, 36 (12.5%) fulfilled this criterion for bone marrow eosinophilia (MDS-Eos); 34 patients (11.8%) showed basophilia (MDS-Bas), and 11 (3.8%) satisfied both criteria (MDS-EosBas). The remaining 229 patients had neither eosinophilia nor basophilia in their bone marrow (MDS(-/-)) at presentation. Cytogenetic analysis was carried out on unstimulated bone marrow cells obtained from 264 patients. When the cytogenetic categorization of the IPSS (International Prognostic Scoring System) for MDS was applied, significantly higher numbers of MDS-Eos and MDS-Bas patients had chromosomal abnormalities carrying intermediate or poor prognosis, compared with the MDS(-/-) patients. Specific chromosomal abnormalities and complex karyotypes were associated with MDS-Eos and/or MDS-Bas. In accordance with these results, the overall survival rate was significantly lower, and the evolution to acute myelogenous leukemia (AML) occurred more frequently in the MDS-Eos and MDS-Bas than in the MDS(-/-) patients. Multivariate analysis demonstrated that bone marrow basophilia was an independent risk factor for evolution to AML. Our study indicates that bone marrow eosinophilia and basophilia in patients with MDS predict a poorer prognosis.
authors.affiliation: Third Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan. tmatsu@showa.gunma-u.ac.jp
authors.forename: Takafumi
authors.initials: T
authors.lastname: Matsushima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yokohama
authors.forename: Jun
authors.initials: J
authors.lastname: Nagasaki
authors.forename: Hiromi
authors.initials: H
authors.lastname: Koiso
authors.forename: Yoshitora
authors.initials: Y
authors.lastname: Kin
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Tohru
authors.initials: T
authors.lastname: Sakura
authors.forename: Norifumi
authors.initials: N
authors.lastname: Tsukamoto
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Karasawa
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Itoh
authors.forename: Hisami
authors.initials: H
authors.lastname: Hirabayashi
authors.forename: Morio
authors.initials: M
authors.lastname: Sawamura
authors.forename: Shogo
authors.initials: S
authors.lastname: Shinonome
authors.forename: Shun-ichi
authors.initials: S
authors.lastname: Shimano
authors.forename: Shuichi
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nojima
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Murakami
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001491:Basophils / Q000473:pathology*; D001853:Bone Marrow / Q000473:pathology*; D002869:Chromosome Aberrations; D018450:Disease Progression; D004802:Eosinophilia / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007951:Leukemia, Myeloid / Q000453:epidemiology; D007958:Leukocyte Count; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D015996:Survival Rate